MicroRNA-33b inhibits tumor cell growth and is associated with prognosis in colorectal cancer patients

• W. Liao ^[1] ; C. Gu ^[1] ; A. Huang ^[1] ; J. Yao ^[1] ; R. Sun ^[1]
  1. [1] Fudan University

     Fudan University

     China

     
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 18, Nº. 5 (May 2016), 2016, págs. 449-456
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose To explore the role of miR-33b in colorectal cancer (CRC) and the correlation between its expression and prognosis.

    Methods The expressions of miR-33b between CRC tissues and normal tissues were measured by real-time PCR. The effects of miR-33b on cell proliferation and cell cycle progression were detected by MTT assay, colony formation assay and flow cytometry. The potential regulations of miR-33b on multiple genes expression were verified by Western blot. Furthermore, the association of miR-33b with CRC clinicopathologic features and prognosis was analyzed by Chi-squared test and Kaplan–Meier tests.

    Results MiR-33b was downregulated in CRC compared with normal colorectal samples and miR-33b inhibited tumor cell growth and induced cell cycle arrest. Western blot assays and correlation analysis showed that miR-33b could regulate multiple growth-related genes. Moreover, the expression of miR-33b was associated with TNM stage and tumor size, and CRC patients with high miR-33b expression had a better prognosis.

    Conclusion Our data suggest that miR-33b functions as a tumor suppressor gene in CRC through regulating cell proliferation and cell cycle.